证券代码：688389 证券简称：普门科技 公告编号：2026-002 本次取得注册证的产品为复合质控品，以样本测量程序测定质控品，将测定 结果进行统计分析或与参考值（参考范围）比较，判断结果是否满足要求，以此 确保公司电化学发光检测系统的安全、有效。 截至本公告披露日，公司及控股子公司已取得 107 个电化学发光配套检测试 剂注册证。上述产品注册证的获得，进一步丰富和完善了公司在体外诊断领域的 产品品种，有利于进一步提升公司在免疫诊断领域的市场竞争力，对公司未来的 经营将产生积极影响。 1 / 2 产品名称 注册 分类 注册证 编号 注册证 有效期至 预期用途 肿瘤标志物 质控品 III 类 国械注准 20253402676 2030 年 12 月 28 日 本质控品与本公司试剂盒配合使用，用于 总前列腺特异性抗原（tPSA）、游离前列 腺特异性抗原（fPSA）、甲胎蛋白（AFP）、 铁蛋白（Ferritin）项目检测时的质量控制； 与重庆普门创生物技术有限公司试剂盒 配合使用，用于癌抗原 125（CA125）、 癌抗原 15-3（CA15-3）、糖类抗原 19-9 （CA19-9）、癌抗原 72-4（CA ...

Group 1 - Company Pumen Technology has recently received a Medical Device Registration Certificate from the National Medical Products Administration of China for its product named "Tumor Marker Quality Control Product" [1] Group 2 - The product is expected to enhance the company's portfolio in the medical device sector, particularly in oncology diagnostics [1] - The announcement reflects the company's ongoing commitment to innovation and compliance with regulatory standards in the healthcare industry [1]

Group 1 - The electronic chemicals sector increased by 3.54% on January 5, with Shanghai Xinyang leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] - Key stocks in the electronic chemicals sector showed significant price increases, with Shanghai Xinyang rising by 11.70% to a closing price of 71.22 [1] Group 2 - The electronic chemicals sector saw a net inflow of 252 million yuan from institutional investors, while retail investors contributed a net inflow of 39.33 million yuan [2] - Major stocks like Nanda Optoelectronics experienced a net inflow of 142.16 million yuan from institutional investors, despite a net outflow from retail investors [3] - The overall trading volume and turnover in the electronic chemicals sector indicated active market participation, with notable transactions in stocks like Shanghai Xinyang and Nanda Optoelectronics [1][2][3]

Core Viewpoint - The company has received a medical device registration certificate for tumor marker quality control products from the National Medical Products Administration, which enhances its competitiveness in the immunodiagnostic market [1] Group 1: Regulatory Approval - The company announced the receipt of the registration certificate for tumor marker quality control products, with the registration number 20253402676, valid until December 28, 2030 [1] - This certificate is intended for quality control during relevant project testing [1] Group 2: Product Portfolio and Market Impact - The company and its subsidiaries have obtained a total of 107 registration certificates for electrochemical luminescence detection reagents [1] - The new registration enriches and improves the variety of the company's in vitro diagnostic products, positively impacting its operations [1] - However, the sales situation of these products remains difficult to predict [1]

Group 1 - Zhuolang Intelligent's subsidiary plans to increase capital by 900 million yuan to its wholly-owned subsidiary in Xinjiang [1] - Zhenhua Heavy Industry signed a contract worth 1.149 billion yuan with Guangzhou Salvage Bureau for a deep-water crane ship construction project [2] - Ugreen Technology intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its global strategy [3] Group 2 - Guangsheng Nonferrous Metals will change its stock name to Zhongxi Rare Metals starting December 31, 2025 [4] - China Electric Research proposed a cash dividend of 2.5 yuan per 10 shares for the first three quarters of 2025 [5] - Chaoyan Co. is establishing a fund with professional investment institutions, aiming to raise 1 billion yuan [6] Group 3 - Silk Road Vision's subsidiary plans to sell 8.5% of Ruijun Technology for 52.7 million yuan [7] - Longgao Co.'s actual controller is transferring 4.37% of the investment development group's equity for 398 million yuan [8] - Weiteou signed a strategic cooperation agreement with Huaruixin Energy to develop new materials and applications [9][10] Group 4 - Annuoqi decided to terminate the investment in a 50,000-ton dye intermediate project due to market changes, with a total investment of 421 million yuan [12] - Akoli's subsidiary has entered trial production for a project with an annual capacity of 20,000 tons of polyether amine [13] - Ningbo Construction's subsidiary signed a construction contract worth 451 million yuan for a comprehensive utility tunnel project [14] Group 5 - Zhejiang Rongtai and Weichuang Electric plan to establish a joint venture in Thailand for R&D and production of mechatronic components [15] - Jiuzhoutong's subsidiary received a drug registration certificate for isopropazine injection [16] - Huaqin Technology's subsidiary signed a daily operation contract worth 392 million yuan [17] Group 6 - ST Meichen completed the sale of 100% equity in Hainan Meichen Ecological Development Co., Ltd. [18] - Pulite's LCP film products have begun mass production for a leading customer in the consumer electronics industry [19][20] - Nanjing Public Utility's major shareholder transferred 7.61% of the company's shares for 300 million yuan [21] Group 7 - Solar Energy terminated the investment in a 150 MW distributed photovoltaic project due to increased investment risks [22] - Yuntian Lifa won a 122 million yuan project for AI development in Longgang [23] - Changchun High-tech's subsidiary received acceptance for a clinical trial application for GenSci141 ointment [24] Group 8 - Changfei Optical Fiber's major shareholder completed a share reduction plan, selling 1.1 million shares for approximately 104.5 million yuan [25] - Sandam Membrane plans to apply for a comprehensive credit limit of up to 100 million yuan for 2026 [26] - Aisecurity received a government subsidy of 3.4611 million yuan [27] Group 9 - Stone Technology's H-share issuance has received approval from the China Securities Regulatory Commission [28] - Hongxing Development's subsidiary plans to suspend production to comply with national hazardous chemical relocation policies [29] - Guodian Nanzi's vice president and chief engineer resigned [30] Group 10 - Jianghe Group's subsidiary won a bid for a city renovation project in Haikou worth approximately 112 million yuan [31] - Gaotie Electric's subsidiary won a bid for a railway project worth 59.0317 million yuan [32] - Huicheng Co. plans to introduce a new partner to its major shareholder [33] Group 11 - Pumen Technology's folic acid testing kit received a medical device registration certificate [34] - Hai Xin Co.'s vitamin B6 injection passed the consistency evaluation for generic drugs [35] - Taiji Group's shareholder plans to merge with its subsidiary [36] Group 12 - Shengyi Electronics adjusted the maximum repurchase price to no more than 144.36 yuan per share [37]

证券代码：688389 证券简称：普门科技 公告编号：2025-087 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于近期收到了1个广东省 药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》， 具体情况如下： 二、对公司的影响 叶酸（Folate），也称为维生素 B9，是一种水溶性 B 族维生素。叶酸在体内 以四氢叶酸（THF）的形式作为辅酶参与多种关键代谢反应，包括 DNA 和 RNA 的合成、氨基酸代谢、血红蛋白的合成以及细胞分裂和增殖等，是人体造血必需 的营养物质之一。叶酸缺乏可引起营养性和巨幼红细胞性贫血、生理功能低下、 胃肠功能紊乱、智力退化以及神经管畸形婴儿的发生。巨幼红细胞性贫血几乎都 是由缺乏叶酸或维生素 B12 之一引起的。 本次取得注册证的叶酸测定试剂盒（电化学发光法），为公司新一代产品， 采用夹心化学发光免疫分析法，进一步提高了试剂的灵敏度、精密度等性能，将 有助于提升公司在贫血检测领域的市场竞争力。 截至本公告披露日，公司及控股子公司 ...

Core Viewpoint - The company has received a medical device registration certificate for its new generation folic acid testing kit, which enhances its competitiveness in the anemia detection market [1] Group 1: Product Development - The company announced the receipt of a registration certificate from the Guangdong Provincial Drug Administration for the folic acid testing kit, classified as a Class II medical device [1] - The product is designed for the quantitative measurement of folic acid levels in human serum or plasma samples, aiding in the diagnosis of megaloblastic anemia [1] - The new testing kit utilizes a sandwich chemiluminescence immunoassay method, improving sensitivity and precision [1] Group 2: Market Position - The company and its subsidiaries have obtained 106 registration certificates for chemiluminescence detection reagents, enhancing the testing menu for its chemiluminescence project [1] - This expansion is expected to strengthen the company's market competitiveness in the immunodiagnostics field [1] Group 3: Future Outlook - The actual sales performance of the product post-launch will depend on future market promotion efforts, and the specific impact on the company's future performance remains unpredictable [1]

Core Viewpoint - The company has received a medical device registration certificate for its new product, a folic acid assay kit, which enhances its market competitiveness in the anemia detection field [1] Group 1: Product Development - The company has obtained the registration certificate from the Guangdong Provincial Drug Administration for the folic acid assay kit, classified as a Class II medical device, with a registration number valid until December 18, 2030 [1] - The folic acid assay kit is designed for the quantitative measurement of folic acid levels in human serum or plasma, aiding in the diagnosis of megaloblastic anemia [1] - This new generation product utilizes a sandwich chemiluminescent immunoassay method, improving the sensitivity and precision of the assay [1] Group 2: Market Position - The company and its subsidiaries have secured a total of 106 registration certificates for chemiluminescent assay kits, further enriching its testing menu in the immunodiagnostic field [1] - The advancements in product offerings are expected to enhance the company's competitiveness in the immunodiagnostic market [1] Group 3: Sales and Market Impact - The actual sales performance of the newly launched product will depend on future market promotion efforts, and the specific impact on the company's future performance remains unpredictable [1]

证券日报网讯 12月23日，普门科技发布公告称，公司于2025年12月23日召开职工代表大会，选举刘敏 女士担任公司第三届董事会职工代表董事。 ...

（文章来源：证券日报） 证券日报网讯 12月23日，普门科技在互动平台回答投资者提问时表示，截至2025年9月30日，公司普通 股股东总数为11859户。 ...